$RLFTF (copy) J-belfort DD A) They’ve been
Post# of 653
(Total Views: 508)
Posted On: 08/16/2020 6:12:23 PM
$RLFTF (copy) J-belfort DD
A) They’ve been designated fast track status and compassionate use by the FDA, not many Covid treatments have this FDA status.
The FDA has just approved a 3rd clinical trial, this one for an inhaler to treat Covid, this potential has to register for any investor.
What an excellent delivery method for an outpatient treatment. Furthermore, they didn’t approve this trial on air, they obviously had some science and data to approve this based on feedback from other clinical trials;
https://clinicaltrials.gov/ct2/results?cond=&...&dist=
C) Have you looked at who is on their data safety monitoring committee?
The Dean of Epidemiology at Johns Hopkins, a Congressman, and a former WH appointed National Science Director.
You can’t truly believe these people would be involved in a pump and dump?
On top of that, based on initial observations the primary endpoints of one of their trials was changed (and as opposite of Remdisivir, it was made to make the outcome even more difficult to prove efficacy); these individuals recommended changing endpoints from mortality at 28 days to free of respiratory failure at 7-10 days, that’s pretty incredible. I trust this DSMC.
Rita Colwell https://en.wikipedia.org/wiki/Rita_R._Colwell
Congressman Andy Harris https://en.wikipedia.org/wiki/Andy_Harris_(politician))
https://www.jhsph.edu/faculty/directory/profi...red-sommer Dean Epidemiology at Johns Hopkins
You think they're in on the pump and dump? DD is your friend. Sure, a lot of lucky idiots stumbled into this one, but also smart money finding it too.
D) Dr Javitt who leads their clinical trials is a heavyweight with a ton of big pharma experience and a wealth of government connections.
Dr. Ram (Chairman) is a leading analyst in the small cap biotech space. All of these pieces weren’t put in place to destroy lifelong built reputations for a pump and dump.
E) A terribly mismanaged company named Cytodyn also with a treatment who stumbles left and right has averaged a market cap that is over triple Relief’s in the last 3 months.
Why can’t they get there? Cytodyn topped out at over $5B, Relief Therapeutics has better connections, better management, and possibly a better product.
F) Oswego Institute reported their study that showed Aviptadil blocks replication of Covid in the lungs (which is what causes death) while also calming cytokines, nothing else has reported anything else even close.
https://relieftherapeutics.com/fda-grants-inh...y-failure/
You can review my comments and try to debunk any of them, but it is all iron clad for now. The clinical trials are happening, positive anecdotal evidence is coming out, legitimate individuals with serious pharma backgrounds are involved, and few treatments look this promising.
I also understand the initial reaction to look at share structure and respond with P&D, but their drug can be worth billions annually.
An inhaled version of a treatment to cure lungs after Covid infection, currently under 3 trials, supported by a large swath of people with excellent reputations, the risk/reward is there IMO and I’ll buy into any selling at this juncture.
Good luck, and I do appreciate any comments and disclosures, I'm obviously long. I’d recommend really diving in here and doing some DD on your own.
Avoid the P&D forums and go find the actual information itself, it's out there and it is impressive. It’s easy to have a slanted opinion when you’ve missed out on massive gains, still healthy up
Disclaimer
All of my posts are just my own opinion and not advice to buy, sell or trade any stock, security or anything else for that matter. I post my own personal thoughts and information that I have found regarding positions that I am invested in.
A) They’ve been designated fast track status and compassionate use by the FDA, not many Covid treatments have this FDA status.
The FDA has just approved a 3rd clinical trial, this one for an inhaler to treat Covid, this potential has to register for any investor. What an excellent delivery method for an outpatient treatment. Furthermore, they didn’t approve this trial on air, they obviously had some science and data to approve this based on feedback from other clinical trials;
https://clinicaltrials.gov/ct2/results?cond=&...&dist=
C) Have you looked at who is on their data safety monitoring committee?
The Dean of Epidemiology at Johns Hopkins, a Congressman, and a former WH appointed National Science Director.
You can’t truly believe these people would be involved in a pump and dump?
On top of that, based on initial observations the primary endpoints of one of their trials was changed (and as opposite of Remdisivir, it was made to make the outcome even more difficult to prove efficacy); these individuals recommended changing endpoints from mortality at 28 days to free of respiratory failure at 7-10 days, that’s pretty incredible. I trust this DSMC.
Rita Colwell https://en.wikipedia.org/wiki/Rita_R._Colwell
Congressman Andy Harris https://en.wikipedia.org/wiki/Andy_Harris_(politician))
https://www.jhsph.edu/faculty/directory/profi...red-sommer Dean Epidemiology at Johns Hopkins
You think they're in on the pump and dump? DD is your friend. Sure, a lot of lucky idiots stumbled into this one, but also smart money finding it too.
D) Dr Javitt who leads their clinical trials is a heavyweight with a ton of big pharma experience and a wealth of government connections.
Dr. Ram (Chairman) is a leading analyst in the small cap biotech space. All of these pieces weren’t put in place to destroy lifelong built reputations for a pump and dump.
E) A terribly mismanaged company named Cytodyn also with a treatment who stumbles left and right has averaged a market cap that is over triple Relief’s in the last 3 months.
Why can’t they get there? Cytodyn topped out at over $5B, Relief Therapeutics has better connections, better management, and possibly a better product.
F) Oswego Institute reported their study that showed Aviptadil blocks replication of Covid in the lungs (which is what causes death) while also calming cytokines, nothing else has reported anything else even close.
https://relieftherapeutics.com/fda-grants-inh...y-failure/
You can review my comments and try to debunk any of them, but it is all iron clad for now. The clinical trials are happening, positive anecdotal evidence is coming out, legitimate individuals with serious pharma backgrounds are involved, and few treatments look this promising.
I also understand the initial reaction to look at share structure and respond with P&D, but their drug can be worth billions annually.
An inhaled version of a treatment to cure lungs after Covid infection, currently under 3 trials, supported by a large swath of people with excellent reputations, the risk/reward is there IMO and I’ll buy into any selling at this juncture.
Good luck, and I do appreciate any comments and disclosures, I'm obviously long. I’d recommend really diving in here and doing some DD on your own.
Avoid the P&D forums and go find the actual information itself, it's out there and it is impressive. It’s easy to have a slanted opinion when you’ve missed out on massive gains, still healthy up
Disclaimer
All of my posts are just my own opinion and not advice to buy, sell or trade any stock, security or anything else for that matter. I post my own personal thoughts and information that I have found regarding positions that I am invested in.
(0)
(0)Mondobiotech Holding AG Basel (RLFTF) Stock Research Links
$MJ
Scroll down for more posts ▼